976-71-6 Canrenone 976-71-6 Canrenone 976-71-6 Canrenone
Product Name: Canrenone
Synonyms: 11614r.p;17-(2-Carboxyethyl)17-hydroxy-3-oxoandrosta-4,6-dienelactone;17-(2-Carboxyethyl)17-hydroxyandrosta-4,6-dien-3-onelactone;17-hydroxy-3-oxo-,gamma-lactone,(17-alpha)-pregna-6-diene-21-carboxylicacid;17-Hydroxy-3-oxo-17-pregna-4,6-diene-21-carboxylicacid-lactone;kanlitong;(1R,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-2,3,3a,3b,7,8,9,9a,9b,10,11,11a-dodecahydrospiro[cyclopenta[a]phenanthrene-1,2';-oxolane]-5'
CAS: 976-71-6
MF: C22H28O3
MW: 340.46
EINECS: 213-554-5
Product Categories: Spironolacrone;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;ASMANEX
Mol File: 976-71-6.mol
Canrenone Chemical Properties
Melting point 158-1600C
alpha D +24.5° (chloroform)
Boiling point 416.25°C (rough estimate)
density 1.1236 (rough estimate)
refractive index 1.5000 (estimate)
storage temp. Store at RT
solubility DMSO: soluble20mg/mL, clear
form powder
color white to beige
optical activity [α]/D +17 to +24°, c = 1 in chloroform-d
Water Solubility 272.4ug/L(25 ºC)
CAS DataBase Reference 976-71-6
NIST Chemistry Reference Canrenone(976-71-6)
Safety Information
Hazard Codes Xn,N
Risk Statements 40-51/53
Safety Statements 36/37-61
RIDADR UN 3077 9 / PGIII
WGK Germany 3
HS Code 29329990
MSDS Information
Canrenone Usage And Synthesis
Chemical Properties Pale yellow to pale Green Solid
Uses Aldosterone antagonist. Diuretic
Uses antiinflammatory, glucocorticoid
Brand name Luvion.
World Health Organization (WHO) Canrenone, which has aldosterone antagonist activity, is a major metabolite of spironolactone and the major metabolite of potassium canrenoate. See WHO comments for potassium canrenoate and spironolactone.
Biological Activity Mineralocorticoid receptor antagonist. Active metabolite of spironolactone ((7a,17a)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid g-lactone ).
Product Name: Canrenone
Synonyms: 11614r.p;17-(2-Carboxyethyl)17-hydroxy-3-oxoandrosta-4,6-dienelactone;17-(2-Carboxyethyl)17-hydroxyandrosta-4,6-dien-3-onelactone;17-hydroxy-3-oxo-,gamma-lactone,(17-alpha)-pregna-6-diene-21-carboxylicacid;17-Hydroxy-3-oxo-17-pregna-4,6-diene-21-carboxylicacid-lactone;kanlitong;(1R,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-2,3,3a,3b,7,8,9,9a,9b,10,11,11a-dodecahydrospiro[cyclopenta[a]phenanthrene-1,2';-oxolane]-5'
CAS: 976-71-6
MF: C22H28O3
MW: 340.46
EINECS: 213-554-5
Product Categories: Spironolacrone;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;ASMANEX
Mol File: 976-71-6.mol
Canrenone Chemical Properties
Melting point 158-1600C
alpha D +24.5° (chloroform)
Boiling point 416.25°C (rough estimate)
density 1.1236 (rough estimate)
refractive index 1.5000 (estimate)
storage temp. Store at RT
solubility DMSO: soluble20mg/mL, clear
form powder
color white to beige
optical activity [α]/D +17 to +24°, c = 1 in chloroform-d
Water Solubility 272.4ug/L(25 ºC)
CAS DataBase Reference 976-71-6
NIST Chemistry Reference Canrenone(976-71-6)
Safety Information
Hazard Codes Xn,N
Risk Statements 40-51/53
Safety Statements 36/37-61
RIDADR UN 3077 9 / PGIII
WGK Germany 3
HS Code 29329990
MSDS Information
Canrenone Usage And Synthesis
Chemical Properties Pale yellow to pale Green Solid
Uses Aldosterone antagonist. Diuretic
Uses antiinflammatory, glucocorticoid
Brand name Luvion.
World Health Organization (WHO) Canrenone, which has aldosterone antagonist activity, is a major metabolite of spironolactone and the major metabolite of potassium canrenoate. See WHO comments for potassium canrenoate and spironolactone.
Biological Activity Mineralocorticoid receptor antagonist. Active metabolite of spironolactone ((7a,17a)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid g-lactone ).
CAS NO:114435-02-8
CAS NO:1541-67-9
CAS NO:423-55-2
CAS NO:1438-82-0
CAS NO:124-41-4
CAS NO:409071-16-5
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View